IO Biotech, Inc.
Clinical-stage biopharma developing dual-action therapeutic cancer vaccines.
IOBT | US
Overview
Corporate Details
- ISIN(s):
- US4497781090
- LEI:
- Country:
- United States of America
- Address:
- OLE MAALOES VEH 3, 2200 COPENHAGEN
- Website:
- https://www.iobiotech.com/
- Sector:
- Manufacturing
Description
IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing novel, immune-modulatory therapeutic cancer vaccines. The company's proprietary T-win technology platform is engineered to create dual-action vaccines that activate the patient's T cells to simultaneously target and eliminate both cancer cells and immune-suppressive cells within the tumor microenvironment. These off-the-shelf therapies are intended to improve outcomes for patients with various solid tumors. The lead product candidate, Cylembio® (IO102-IO103), is being evaluated in clinical trials for melanoma and other cancers, while additional pipeline candidates are in preclinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all IO Biotech, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for IO Biotech, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for IO Biotech, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
